– 1 –
1st Proof • 06/11/2007 • Biosino • 071001476ann(Client/Syntxt(MD&A))
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION


(Incorporated in the People’s Republic of China with limited liability)
(Stock Code: 8247)
THIRD QUARTERLY RESULTS ANNOUNCEMENT
FOR THE THREE MONTHS AND NINE MONTHS ENDED 30 SEPTEMBER 2007

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (THE “GEM”)
OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK
EXCHANGE”)
GEM has been established as a market designed to accommodate companies to which a high
investment risk may be attached. In particular, companies may list on GEM with neither a track
record of profitability nor any obligation to forecast future profitability. Furthermore, there may
be risks arising out of the emerging nature of companies listed on GEM and the business sectors or
countries in which the companies operate. Prospective investors should be aware of the potential
risks of investing in such companies and should make the decision to invest only after due and
careful consideration. The greater risk profile and other characteristics of GEM mean that it is a
market more suited to professional and other sophisticated investors.
Given the emerging nature of companies listed on GEM, there is a risk that securities traded on
GEM may be more susceptible to high market volatility than securities traded on the Main Board
and no assurance is given that there will be a liquid market in the securities traded on GEM.
The principal means of information dissemination on GEM is publication on the internet website
operated by the Stock Exchange. Listed companies are not generally required to issue paid
announcements in gazetted newspapers. Accordingly, prospective investors should note that they
need to have access to the GEM website in order to obtain up-to-date information on GEM-listed
companies.

This announcement, for which the directors (the “Directors”) of Biosino Bio-Technology and Science
Incorporation (the “Company”) collectively and individually accept full responsibilities, includes
particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the “GEM
Listing Rules”) of the Stock Exchange for the purpose of giving information with regard to the Company.
The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and
belief: (1) the information contained in this announcement is accurate and complete in all material
respects and not misleading; (2) there are no other matters the omission of which would make any
statement in this announcement misleading; and (3) all opinions expressed in this announcement have
been arrived at after due and careful consideration and are founded on bases and assumptions that are
fair and reasonable.


– 2 –
1st Proof • 06/11/2007 • Biosino • 071001476ann(Client/Syntxt(MD&A))
THE THIRD QUARTERLY RESULTS FOR THE THREE MONTHS AND NINE
MONTHS ENDED 30 SEPTEMBER 2007

The Board of Directors (the “Board”) of the Company announced the unaudited consolidated results of
the Company and its subsidiaries (collectively referred to as the “Group”) for the three months and nine
months ended 30 September 2007, together with the comparative figures for the same period in 2006, as
follows:
CONDENSED CONSOLIDATED INCOME STATEMENT

Three months ended Nine months ended
30 September 30 September
2007 2006 2007 2006

Unaudited Unaudited Unaudited Unaudited
Notes RMB’000 RMB’000 RMB’000 RMB’000
REVENUE 3 46,612 38,541 130,264 106,711

Cost of sales (16,315) (12,305) (45,633) (34,830)
Gross profit 30,297 26,236 84,631 71,881
Other income 3,343 126 7,031 570
Selling and distribution expenses (11,252) (10,820) (29,834) (28,641)
Administrative expenses (9,062) (7,137) (28,838) (19,459)
Research and development costs (2,588) (1,698) (7,606) (5,727)
Other operating expenses (83) – (639) –
PROFIT FROM OPERATING
ACTIVITIES 10,655 6,707 24,745 18,624

Finance costs (1,394) (1,291) (4,126) (2,335)
PROFIT BEFORE TAX 9,261 5,416 20,619 16,289

Tax 4 (2,223) (857) (5,517) (2,481)
PROFIT FOR THE PERIOD 7,038 4,559 15,102 13,808

Attributable to:
Shareholders of the Company 6,632 4,532 13,814 13,214
Minority interests 406 27 1,288 594
7,038 4,559 15,102 13,808
EARNINGS PER SHARE
ATTRIBUTABLE TO
SHAREHOLDERS OF
THE COMPANY 5

– Basic (RMB) 0.07 0.05 0.14 0.13
– Diluted N/A N/A N/A N/A

– 3 –
1st Proof • 06/11/2007 • Biosino • 071001476ann(Client/Syntxt(MD&A))
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
1. CORPORATE INFORMATION

Biosino Bio-Technology and Science Incorporation (the “Company”) is a limited liability company incorporated in the
People’s Republic of China (the “PRC”). The registered office of the Company is located at No. 27, Chaoqian Road,
Science and Technology Industrial Park, Changping District, Beijing, the PRC. H shares of the Company were listed
on the Growth Enterprise Market (the “GEM”) of
During the period, the Group principally engaged in the manufacture, sale and distribution of in-vitro diagnostic
reagent products and a pharmaceutical product.
2. BASIS OF PREPARATION

The unaudited condensed accounts have been prepared in accordance with Hong Kong Financial Reporting Standards
(“HKFRSs”) (which also include Hong Kong Accounting Standards (“HKASs”) and Interpretations) issued by the
Hong Kong Institute of Certified Public Accountants (“HKICPA”) and accounting principles generally accepted in
Hong Kong. The accounting policies and basis of preparation used in the preparation of the unaudited condensed
accounts are consistent with those used in the Company’s audited financial statements for the year ended 31 December
2006.
3. REVENUE

Revenue, which is also the Group’s turnover, represents the net invoiced value of goods sold, net of value added tax
and government surcharges, and after allowances for the goods returned and trade discounts.
An analysis of the Group’s revenue is as follows:
Three months ended Nine months ended
30 September 30 September
2007 2006 2007 2006

Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000
Sale of in-vitro diagnostic reagent products 30,450 24,439 84,476 68,091
Sale of a pharmaceutical product 16,162 14,102 45,788 38,620
46,612 38,541 130,264 106,711

– 4 –
1st Proof • 06/11/2007 • Biosino • 071001476ann(Client/Syntxt(MD&A))
4. TAX

No provision for Hong Kong profits tax has been made as the Company and its subsidiaries have not generated any
assessable profits in Hong Kong since their respective dates of incorporation. Taxes on profits assessable elsewhere
have been calculated at the rates of tax prevailing in the country in which the Group operates, based on existing
legislation, interpretations and practices in respect thereof. According to the relevant PRC income tax law, the
Company and its subsidiaries, being registered as new and high technology enterprises in Beijing, are entitled to a
concessionary income tax rates of 15% and 7.5% in their respective subsidiaries, which have been applied for both
periods.
Three months ended Nine months ended
30 September 30 September
2007 2006 2007 2006

Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000
Group:
Current – Mainland China 2,223 857 5,517 2,481
5. EARNINGS PER SHARE

The calculation of basic earnings per share for the three months ended 30 September 2007 is based on the unaudited
profit attributable to shareholders of the Company for the period and the weighted average of 100,017,528 (2006:
100,017,528) registered shares in issue during the period.
The calculation of basic earnings per share for the nine months ended 30 September 2007 is based on the unaudited
profit attributable to shareholders of the Company for the period and the weighted average of 100,017,528 (2006:
92,980,491) registered shares in issue during the period.
No diluted earnings per share have been presented as no diluting event existed during the three months and nine
months ended 30 September 2007 (2006: Nil).

– 5 –
1st Proof • 06/11/2007 • Biosino • 071001476ann(Client/Syntxt(MD&A))
6. RESERVES

The movements of reserves for the nine months ended 30 September 2007 and 2006 are as follows:
Issued Proposed
share Capital Statutory Retained final
capital reserves
#
reserves profits dividend Total
Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000
At 1 January 2006 70,018 7,544 17,286 7,810 10,002 112,660
Proceeds from issue of shares 30,000 32,400 – – – 62,400
Share issuance costs – (13,501) – – – (13,501)
Profit for the period
attributable to shareholders
of the Company – – – 13,214 – 13,214
Final 2005 dividend declared – – – – (10,002) (10,002)
At 30 September 2006 100,018 26,443 17,286 21,024 – 164,771
At 1 January 2007 100,018 30,309 20,179 10,344 10,002 170,852
Profit for the period
attributable to shareholders
of the Company – – – 13,814 – 13,814
Final 2006 dividend declared – – – – (10,002) (10,002)
At 30 September 2007 100,018 30,309 20,179 24,158 – 174,664
# The capital reserves of the Group include non-distributable reserves of the Company and its subsidiaries created in
accordance with accounting and financial regulations of the PRC.
7. INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the nine months ended 30 September 2007
(2006: Nil).

– 6 –
1st Proof • 06/11/2007 • Biosino • 071001476ann(Client/Syntxt(MD&A))
MANAGEMENT DISCUSSION AND ANALYSIS
BUSINESS REVIEW FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2007

The revenue for the nine months ended 30 September 2007 was approximately RMB130 million,
representing an increase of 22.10% as compared with approximately RMB107 million for the corresponding
period last year. During the period, the revenue of approximately RMB84.48 million was generated from
the sales of in-vitro diagnostic reagents which accounted for 64.85% of the Group’s total revenue,
representing a 24.06% increase as compared with RMB68.09 million for the corresponding period last
year. For pharmaceutical products, the revenue of RMB45.79 million of Lumbrokinase capsules accounted
for 35.15% of the Group’s total revenue, representing an increase of 18.56% as compared with RMB38.62
million for the corresponding period last year.
For the nine months ended 30 September 2007, profit from operating activities amounted to RMB24.75
million, representing an increase of 32.9% as compared with the corresponding period last year. Despite
the consolidation of the operational expenses of new subsidiaries and higher research and development
expenses for continued effort of new products, there was still a growth in profit from operating activities
because of satisfactory increase in revenue.
Profit attributable to shareholders for the nine months ended 30 September 2007 was RMB13.81 million,
representing an increase of approximately 4.6% as compared with the corresponding period last year.
Such increase was mainly attributable to the increase in revenue and profit from operating activities,
which completely offset the increase in interest expenses as a result of the increase in the bank borrowings
for research and development and business expansion, and higher income tax expense as a result of the
adjustment in the fixed deductible amount on salary expenses imposed by State Administration of Taxation.
PROSPECT AND FUTURE OUTLOOK

It is expected that the economy of China will continue to grow stably with improvement in living
standard and health consciousness of people. The PRC government is going to introduce new social
medical protection policies which will facilitate the healthy and stable development of clinical diagnostic
products and pharmaceutical products. As such, China will remain one of the world’s fastest growing
markets of these industries.
Looking forward, the Directors believe that the market share of our products will be expanded steadily
throughout the result of our gradual endeavour and timely effort for market development. The overseas
sales of our diagnostic products will rise after some of our diagnostic reagents have passed the “CE”
certification.
The research and development and the sales model of the entire medical industry will be changed upon
the introduction and implementation of new social medical protection policies of the state. Baiao
Pharmaceuticals, the inventor of Lumbrokinase, will be well-positioned to benefit from the rectification
and improvement of the medical market order of the state.
The Group is confident that our market share and return of shareholders will be increased as a result of
our continuous efforts in research and development in order to launch more new products and enhance
promotion effort in the near future.

– 7 –
1st Proof • 06/11/2007 • Biosino • 071001476ann(Client/Syntxt(MD&A))
OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES
Neither the Company, nor any of its subsidiaries purchased, sold or redeemed any of the Company’s
listed securities during the period.
COMPLIANCE ADVISER’S INTEREST
As updated and notified by the Company’s compliance adviser, Partners Capital International Limited
(the “Compliance Adviser”), none of the Compliance Adviser, or its directors, employees or associates
(as defined under the GEM Listing Rules) had any interest in the share capital of the Company as at 30
September 2007 pursuant to Rule 6.36 of the GEM Listing Rules.
Pursuant to an agreement dated 27 February 2006 entered into between the Company and the Compliance
Adviser, the Compliance Adviser will receive a fee for acting as the Company’s compliance adviser for
the period from 27 February 2006 to 31 December 2008 or until the agreement is terminated in accordance
with the terms and conditions set out therein.
AUDIT COMMITTEE

The Company has established an audit committee on 10 February 2006 with written terms of reference in
compliance with the requirements as set out in Rules 5.28 and 5.29 of the GEM Listing Rules. The audit
committee’s primary duties are the review and supervision of the Company’s financial reporting procedures
and internal control system. The Group’s unaudited condensed accounts for the period have been reviewed
by the audit committee with the three independent non-executive directors of the Company, namely Dr.
Cheng Jing (appointed on 9 January 2007), Dr. Hua Sheng and Mr. Chan Yiu Kwong.
COMPLIANCE WITH CODE ON CORPORATE GOVERNANCE PRACTICES

The Company always puts strong emphasis on the superiority, steadiness and rationality of corporate
governance. The Company has complied with all the code provisions in the Code on Corporate Governance
Practice (the “Code”) by establishing a formal and transparent procedures to protect and maximise the
interests of shareholders during the period under review, except for the deviation that Mr. Wu Lebin
assumes the role of both the chairman of the Board and the president of the Company.
By order of the Board
Biosino Bio-Technology and Science Incorporation
Mr. Wu Lebin
Chairman
Beijing, the PRC, 8 November 2007

– 8 –
1st Proof • 06/11/2007 • Biosino • 071001476ann(Client/Syntxt(MD&A))
As at the date of this announcement, the Board of the Company comprises:
Chairman and Executive Director
Mr. Wu LebinN!s[
Vice Chairman and Non-executive Directors
Mr. Zhang Yongu[and Dr. Gao Guang Xia{
Executive Directors
Dr. Wang Lin{and Mr. Hou QuanminO[
Non-executive Directors
Ms. Li Chang~{, Mr. Rong Yangq[, Mr. Wang Fu GenE[and Ms. Yu
XiaominO~{
Independent non-executive Directors
Dr. Cheng Jing/{, Dr. Hua Sheng6[{and Mr. Chan Yiu Kwong4[
This announcement, for which the Directors collectively and individually accept full responsibility, includes
particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise
Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard
to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their
knowledge and belief, (1) the information contained in this announcement is accurate and complete in all
material respects and not misleading; (2) there are no other matters the omission of which would make
any statement in this announcement misleading; and (3) all opinions expressed in this announcement
have been arrived at after due and careful consideration and are founded on bases and assumptions that
are fair and reasonable.
This announcement will remain on the GEM website with the domain name of www.hkgem.com on the
“Latest Company Announcements” page for at least 7 days from the date of its posting.